A new study published in Cell Death & Disease has identified a critical role for Piezo1-mediated autophagy in promoting immune-inflammatory responses in ankylosing spondylitis (AS), offering fresh insights into disease mechanisms and highlighting a potential new therapeutic target.
Although the exact mechanisms driving AS remain incompletely understood, growing evidence suggests that immune dysregulation, inflammatory signaling, and abnormal bone remodeling all contribute to disease progression. The study focused on Piezo type mechanosensitive ion channel component 1 (Piezo1), a recently identified mechanosensitive cation channel that responds to mechanical stimuli such as matrix stiffness, shear stress, and tissue tension. Piezo1 is widely expressed in both immune and non-immune cells, including macrophages, neutrophils, endothelial cells, osteoblasts, osteoclasts, and fibroblast-like synoviocytes (FLS).
Researchers noted that mechanosensitive ion channels, particularly Piezo1, have emerged as important regulators of immune cell behavior. Under physiological conditions, Piezo1 helps maintain tissue homeostasis by converting mechanical signals into intracellular calcium signaling pathways that regulate immune cell activation, migration, cytokine production, and tissue repair. However, dysregulated Piezo1 activity has increasingly been implicated in chronic inflammation and immune-mediated diseases.
In the current study, investigators found that Piezo1 expression was significantly elevated in patients with AS compared with healthy controls. Higher Piezo1 expression also positively correlated with disease activity, disease duration, and markers of autophagy. Mechanistic analyses revealed that increased Piezo1 expression promoted M1 polarization of monocyte-derived macrophages, thereby enhancing autophagy and stimulating the release of pro-inflammatory mediators. In fibroblast-like synoviocytes, Piezo1 activation similarly increased autophagy and interleukin-6 (IL-6) signaling, both of which are strongly associated with chronic inflammatory responses in AS.
To further investigate the therapeutic potential of targeting Piezo1, researchers utilized the proteoglycan-induced arthritis (PGIA) model. Treatment with GsMTx4, a Piezo1 inhibitor, suppressed excessive autophagy activation, reduced inflammatory responses, and demonstrated protective effects on spinal bone tissue. Immunofluorescence studies further confirmed reduced autophagy activity and lower inflammatory cytokine expression in macrophages and fibroblast-like synoviocytes following Piezo1 inhibition.
According to the authors, this is the first study to demonstrate the role of Piezo1-mediated autophagy in driving immune-inflammatory responses in ankylosing spondylitis. The findings suggest that dysregulated mechanosensitive signaling may contribute directly to AS pathogenesis and identify Piezo1 as a promising therapeutic target for future intervention strategies.
The researchers concluded that inhibition of Piezo1 may help prevent excessive autophagy activation, attenuate inflammation, and protect spinal structures in AS, potentially opening new avenues for targeted treatment development in chronic inflammatory arthritis.
References
- Zhao H, Yu X, Jiang M, Li Z, Zhao Y, Ren Y, et al. Piezo1-mediated autophagy promotes immune-inflammatory responses in ankylosing spondylitis. Cell Death Dis. 2026;17(1):12.
- Zhu Y, Tang A, Xiao Q, Hu J. The role of Piezo1 in the immune system in health and disease. J Med Biomed Discoveries. 2025;7:145.
- Yang J, Xu C, Xie X, Wang J, Shi P. Roles of Piezo1 in chronic inflammatory diseases and prospects for drug treatment. Mol Med Rep. 2025;32:200.